Abstract

A hydroxamic acid moiety has been demonstrated as the key structural element in many highly potent and selective inhibitors against a variety of metalloprotease enzymes, such as MMPs, TACE, HDAC, PDF, etc. Over the last several years, there has been a rapid growth of literature and patent applications dealing with the development of the hydroxamic acid-based inhibitors. This review highlights the most recent examples to show their potential therapeutic applications.

Keywords: hydroxamic acids, mmps, tace, hdac, hydroxamic acid-based inhibitors